Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies.  The Company's main product is Abata cept which is for arthritis treatment

Material Business Matters Related to Investment Decisions(MFDS approval of BLA for Stoboclo & Osenvelt (CTP41, Prolia & Xgeva Biosimilar))

Decision on Acquisition of Treasury Stock

Material Business Matters Related to Investment Decisions(ì¤í ë³´í´ë¡&ì¤ì¼ë²¨í¸(CTP41, íë¡¤ë¦¬ì&ìì¤ì§ë° ë°ì´ì¤ìë°ë¬) íêµ­(MFDS) íëª©íê° íë)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Celltrion Inc (068270 KS)

Material Business Matters Related to Investment Decisions(MFDS approval of BLA for Stoboclo & Osenvelt (CTP41, Prolia & Xgeva Biosimilar))

Decision on Acquisition of Treasury Stock

Material Business Matters Related to Investment Decisions(ì¤í ë³´í´ë¡&ì¤ì¼ë²¨í¸(CTP41, íë¡¤ë¦¬ì&ìì¤ì§ë° ë°ì´ì¤ìë°ë¬) íêµ(MFDS) íëª©íê° íë)

[Revised] New Facility Investment, etc.

Interim Report on Business Performance (Fair Disclosure)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Material Business Matters Related to Investment Decisions(MFDS approval of BLA for Stoboclo & Osenvelt (CTP41, Prolia & Xgeva Biosimilar))

Decision on Acquisition of Treasury Stock

Material Business Matters Related to Investment Decisions(ì¤í ë³´í´ë¡&ì¤ì¼ë²¨í¸(CTP41, íë¡¤ë¦¬ì&ìì¤ì§ë° ë°ì´ì¤ìë°ë¬) íêµ­(MFDS) íëª©íê° íë)

[Revised] New Facility Investment, etc.

Interim Report on Business Performance (Fair Disclosure)

Material Business Matters Related to Investment Decisions(ì¤í ë³´í´ë¡&ì¤ì¼ë²¨í¸(CTP41, íë¡¤ë¦¬ì&ìì¤ì§ë° ë°ì´ì¤ìë°ë¬) íêµ(MFDS) íëª©íê° íë)